CGTLive®’s Weekly Rewind – April 19, 2024
Review top news and interview highlights from the week ending April 19, 2024.
CGTLive®’s Weekly Rewind – April 19, 2024
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. A Slow Embrace: Hemophilia's Gradual Adoption of Gene Therapy
For World Hemophilia Day, CGTLive took a look at how the hemophilia field has adapted to the introduction of gene therapy to the treatment landscape.
2. John DiPersio, MD, PhD, on Ongoing Advancements in Stem Cell Transplantation and Cell Therapy
The director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine discussed novel innovations that lie on the horizon.
3. 4DMT Aligns on Path Forward for Cystic Fibrosis Gene Therapy
The company plans to initiate a pivotal trial of 4D-710 in the second half of 2025.
4. PJ Brooks, PhD, on Developing New Strategies for Novel Clinical Trials
The deputy director, Division of Rare Diseases Research Innovation, NCATS, NIH, discussed the NIH’s genome editing program and more.
5. MCO-010 Phase 2b Data Supports BLA Submission for Retinitis Pigmentosa
Nanoscope Therapeutics received feedback from the FDA endorsing significant change in BCVA as a primary endpoint supporting approval.
Will the CMS CGT Model Support Patient Access to Sickle Cell Disease CGTs?
July 25th 2024Cell and gene therapies can transform the paradigm of care for patients with chronic, complex conditions, but these therapies come at an up-front cost of several million dollars per treatment, complicating the pipeline of access to them.
